ClinicalTrials.gg
RecruitingNCT07407790SNAPSUpdated Feb 12, 2026

The Southern-Norway Post-Stroke Atrial Fibrillation Study

An interventional study of Patch ECG and Standard Care (in control arm) in Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke) and Ischemic Stroke, sponsored by Sorlandet Hospital HF. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Sorlandet Hospital HF · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies in Atrial Fibrillation with a site in Norway — 8 open to participants now, 13 under way, 1 of them phase 3. Atrial Fibrillation · Norway.

Planned enrollment
27th of 53
450 · median 450
Started
2026
with 2 others
No phase
23 of 70
3 open now
Primary completion
2028-12
later than 9 of 12 live
Registered
68th of 70
by date
Lead sponsor
3 of 70
Sorlandet Hospital HF

Among the 70 studies in Atrial Fibrillation with a site in Norway, this one is the 27th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2026, is one of 23 with no phase, reaches primary completion later than 9 of the 12 other live ones, and was the 68th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 70 studies in Atrial Fibrillation with a site in Norway are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Atrial Fibrillation with a site in Norway, or all of them as a file.
02

Study summary

This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but it can be difficult to catch because it often comes and goes.

The study will include approximately 450 adults who have had a stroke or a transient "mini-stroke" (TIA) within the last two weeks. Participants will be assigned by chance (randomized) to one of two groups:

  • Group 1 (Intervention): Participants wear the "ECG247 Smart Heart Sensor." This is a small patch that sticks to the chest and connects to a smartphone. It is worn continuously for up to 14 days, even after leaving the hospital.
  • Group 2 (Standard Care): Participants receive the standard hospital check-up. This typically involves using a "Holter monitor" (a device with wires and electrodes) for a period of about 24 to 48 hours some time after leaving the hospital.

The main goal is to see if the procedure using the patch is equal to the standard procedure in detecting atrial fibrillation in participants. The study will also measure how quickly doctors can start the correct medication and how easy the patients find the devices to use.

Read the detailed description

Background and Rationale Atrial fibrillation (AF) is a major risk factor for ischemic stroke, yet it often goes undetected due to its paroxysmal (intermittent) nature. While guidelines recommend prolonged heart rhythm screening after a stroke of undetermined cause, standard hospital practice often relies on short-term telemetry and ambulatory Holter monitoring. These standard methods can be limited by device availability, bulkiness, and short monitoring duration (typically 24-48 hours), potentially leading to under-diagnosis of AF.

This study aims to evaluate the clinical utility and cost-effectiveness of a novel, continuous patch ECG system (ECG247) initiated in the hospital setting compared to standard care.

Study Design This is a prospective, randomized, parallel-group, open-label (no masking) study conducted at a single stroke center. Approximately 450 eligible patients will be enrolled.

Recruitment and Stratification Patients admitted with ischemic stroke or transient ischemic attack (TIA) within the last two weeks are screened for eligibility, aiming for inclusion within 48 hours of admission. Participants are randomized in a 1:1 ratio to either the intervention arm or the standard care arm. Randomization is stratified by age into three groups: 18-64 years, 65-74 years, and ≥75 years.

Intervention Arm (ECG247 Smart Heart Sensor) Patients in this group will have the ECG247 patch applied to the anterior chest wall while in the hospital.

  • Device: The ECG247 is a wireless, water-resistant patch sensor that connects to a dedicated smartphone application via Bluetooth. It transmits data to a secure cloud service for analysis.
  • Duration: The device is worn continuously for up to 14 days. Monitoring begins in-hospital and continues after discharge.
  • Analysis: The system utilizes an algorithm to detect arrhythmia. Episodes of AF >30 seconds are considered positive findings. Study personnel and physicians verify algorithm-detected episodes.
  • Concurrent Care: These patients also receive standard in-house telemetry per hospital protocol while admitted.

Control Arm (Standard Care) Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines.

  • In-hospital: Monitoring via continuous telemetry or intermittent ECGs based on availability and clinical priority.
  • Ambulatory: Upon discharge, patients are referred for ambulatory Holter monitoring. The duration is typically 24-48 hours as decided by the treating cardiologist.
  • Analysis: Holter recordings are analyzed by trained technicians and reviewed by a cardiologist.

Biomarker Analysis Blood samples will be collected from all participants to analyze N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The study will assess the association between NT-proBNP levels and the detection of silent AF to evaluate its potential for risk stratification.

Outcomes and Follow-up

  • Primary Outcome: The detection rate of AF (defined as episodes ≥30 seconds).
  • Secondary Outcomes: Time to AF detection, time to initiation of anticoagulation therapy, total monitoring duration, and health economics.
  • User Experience: Patients in the intervention group will complete Patient Reported Experience Measures (PREMs) regarding usability and satisfaction.
  • Long-term Follow-up: Participants will be followed for up to 12 months to assess clinical endpoints, including secondary stroke, TIA, and major bleeding.
03

Conditions studied

  • Atrial Fibrillation (AF)
  • Atrial Fibrillation (Prevention of Stroke)
  • Ischemic Stroke
  • Secondary Prevention
  • Arrhythmia Atrial

Keywords

  • stroke
  • atrial fibrillation
  • anticoagulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients hospitalized with an ischemic stroke or (TIA), including amaurosis fugax, occurring within the last 2 weeks.
  • Initial evaluation of CT and/or CT angiography and/or MRI supports a diagnosis of TIA or ischemic stroke.
  • Available smartphone and access to the ECG247-app to be able to participate in the study.
  • Estimated life span of >6 month
  • Permanent address in Norway
  • , Capable of giving signed informed consent or consent through proxy as described in Appendix which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions

  • Known AF or atrial flutter prior to inclusion
  • Concomitant use of anticoagulation therapy or established to its use. To date this includes apixaban, rivaroxaban, edoxaban, dabigatran, warfarin and indirect thrombin inhibitors (except for short term thrombosis prevention).
  • Implanted pacemaker, ICD or loop-recorder
  • >70% stenosis of carotid artery on ipsilateral side to the stroke on CT angiography or ultrasound
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Intervention Arm (ECG247 Smart Heart Sensor)

    Patients in this group will have the ECG247 patch applied to the anterior chest wall while in the hospital. * Device: The ECG247 is a wireless, water-resistant patch sensor that connects to a dedicated smartphone application via Bluetooth. It transmits data to a secure cloud service for analysis. * Duration: The device is worn continuously for up to 14 days. Monitoring begins in-hospital and continues after discharge. * Analysis: The system utilizes an algorithm to detect arrhythmia. Episodes of AF \>30 seconds are considered positive findings. Study personnel and physicians verify algorithm-detected episodes. * Concurrent Care: These patients also receive standard in-house telemetry per hospital protocol while admitted.

    Device: Patch ECG

  • Other
    Control Arm (Standard Care)

    Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines. * In-hospital: Monitoring via continuous telemetry or intermittent ECGs based on availability and clinical priority. * Ambulatory: Upon discharge, patients are referred for ambulatory Holter monitoring. The duration is typically 24-48 hours as decided by the treating cardiologist. * Analysis: Holter recordings are analyzed by trained technicians and reviewed by a cardiologist.

    Device: Standard Care (in control arm)

Interventions

  • DevicePatch ECG

    This study aims to evaluate the clinical utility and cost-effectiveness of a novel, continuous patch ECG system (ECG247) initiated in the hospital setting compared to standard care.

  • DeviceStandard Care (in control arm)

    Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines.

06

What researchers measure

Primary outcomes

  1. Detection rate of atrial fibrillation

    The detection rate of AF (defined as episodes ≥30 seconds). Analysis will be performed on an intention-to-treat basis, and AF detection will be primarily assessed for its non-inferiority and secondarily for difference in proportions. An interim analysis for efficacy measures will be performed using the O'Brien-Flemming correction for the primary endpoint AF detection rate after 72 and 144 participants in each arm.

    Time frame: From enrollment to the end of heart rate monitoring. Will also be registered on follow up after 12 months.

  2. Time from enrollment to treatment initiation with anticoagulant medicine

    Days from enrollment until AF detection results in change of prophylactic treatment, defined as prescribed anticoagulant medication collected by the patient, retrieved from e-prescription data accessed through the Summary Care Record (Kjernejournal).

    Time frame: From enrollment until end of follow up (12 months after enrollment).

  3. Time from enrollment to detection of first AF episode

    Time to detection of first episode of atrial fibrillation after hospital admission

    Time frame: From enrollment up to 1 year

  4. Total duration of heart rate monitoring

    Total duration of heart rate monitoring, also including an assessment of device signal quality for assessment

    Time frame: From enrollment up to 1 year

  5. Numbers of participants with secondary stroke/TIA and/or major bleeding

    Assessing secondary stroke and major bleeding at 1 year of follow-up

    Time frame: From enrollment to one-year follow up, assessed at 1-year follow up.

Secondary outcomes

  1. Explore the practical utility in regards to validity of results of AF screening after a stroke with a patch ECG

    Inter-rater validity of ECG results between the ECG247 algorithm, cardiologists and neurologists

    Time frame: After 1 year of recruitment

  2. Explore the practical utility of time consumed using AF screening after a stroke with a patch ECG

    A suitable number of observations will be performed to evaluate the time needed to complete the patch ECG attachment and inform the patient, interpret the results and follow-up of results

    Time frame: After 1 year of recruitment

  3. Explore the practical utility and reliability of AF screening after a stroke with a patch ECG

    Reliability of the monitoring device in crude versus interpretable monitoring duration in hours. Reliability will be assessed by the study personnel when creating the patch ECG result record. The whole pulse rate strip will be analyzed to identify periods of 1\>h with a lack of signal or reduced signal quality. The total monitoring duration registered by the algorithm in hours versus manual interpretation with readable signal in hours will be evaluated as a percentage: Useable monitoring time/Total monitoring time x 100% = Percentage of useful monitoring.

    Time frame: Assessed at 1 year after enrollment start

  4. Explore the practical utility and patient satisfaction of AF screening after a stroke with a patch ECG

    Patient Reported Experience Measures (PREMs) to all patients in interventional arm within a month of discharge and within 1 month of Holter completion for control arm, registration of technical problems, allergic reactions to patch, photo of patch placement and registration of patients not considered eligible to the study due to lack of smartphone and other causes not listed in the exclusion/inclusion criteria. PREMS will be reported by a 7 point Likert scale, with higher values indicating a high level of satisfaction.

    Time frame: Through study completion

  5. Diagnostic quality of in-house patch ECG compared to telemetry

    Sensitivity and specificity of AF detection in patch ECG compared to concomitant telemetry. Assessment of detection of other dangerous arrhythmias in patch ECG compared to telemetry. Quality of signal from telemetry compared to patch ECG. In the subgroup of patients where patch ECG and telemetry are worn simultaneously, the results of both methods will be cross-validated against each other

    Time frame: From start of enrollment until discharge of last included patient

  6. Cost effectiveness of patch ECG compared to standard care

    Cost-effectiveness analysis of patch ECG and standard care with the endpoint being reduced secondary stroke

    Time frame: From enrollment until end of follow up.

  7. Assess predictors of silent AF

    Association between clinical, radiological and laboratory factors (including) NT-pro-BNP level and AF NT-proBNP will be assessed upon inclusion and can be analyzed from blood samples drawn on day 1 after admission. MRI results Echocardiography results CHADSVASC, age, gender, medication used, previous diseases, BMI

    Time frame: From enrollment until end of patient follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Currently undecided regarding the sharing of IPD. No established formal cooperation agreements with external research groups to date. Any future decision to share data will depend on the establishment of such collaboration agreements in adherence to data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 35 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2026
First posted
Feb 12, 2026
StartActual
Jan 10, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07407790
Lead sponsor
Sorlandet Hospital HF
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Jan 10, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Feb 12, 2026

Study contacts

Halvor Oeygarden, PhD
Contact
halvor.oygarden@sshf.no
+4747621336
Ivana Sapina, PhD student
Contact
ivana.sapina@sshf.no
+47 47311701

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion